Aim: To clarify whether plasma lipoproteins, including Lp(a), can predict relapse pattern in the first years after diagnosis of nephrotic syndrome (NS), we evaluated them in patients with steroid-sensitive NS. Methods: We analyzed the medical records of 35 patients with steroid-sensitive NS who were seen by us from January 1992 to December 1999 followed for at least 1 year. These patients were divided into two groups. Group 1 consisted of 20 patients who infrequently relapse (IR: <2 in 6 months or <3 in a year), group 2 consisted of 15 patients who frequently relapse (FR: ≥2 in 6 months or ≥3 in a year). Clinical and laboratory findings such as age at onset, gender, urinalysis, serum level of total protein, albumin, and concentrations of serum lipid including lipoprotein(a) (Lp(a)) were investigated between group 1 and group 2. Results: The concentration of plasma Lp(a) in group 2 was higher than that in group 1 (81.0 ± 35.2 vs. 35.9 ± 26.5 mg/dl, p < 0.01). On multivariate analysis using logistic regression model, the concentration of plasma Lp(a) was an independent risk factor for relapse of NS. Conclusions: Our findings suggest that of all the laboratory data examined, high values of Lp(a) can predict future relapse of NS and should be well documented.

Keywords:
Lipoprotein(a), Steroid-sensitive nephrotic syndrome, Children
1.
Haffner SM, Gruber KK, Aldrete G, Morales PA, Stern MP, Tuttle KR: Increased Lipoprotein(a) in chronic renal failure. J Am Soc Nephrol 1992;3:1156–1162.
2.
Barbagallo CM, Averna MR, Sparacino V, GalioneA, Capoto F, Scafidi V, Amato S, Mancino C, Cefalu AB, Notarbartolo A: Lipoprotein(a) levels in end-stage renal failure and renal transplantation. Nephron 1993;64:560–564.
3.
Garnotel R, Roussel B, Pennaforte F, Randoux A, Gillery P: Changes in serum lipoprotein(a) levels in children with corticosensitive nephritic syndrome. Pediatr Nephrol 1996;10:699–701.
4.
Confield D, Schwartz MW: Nephrosis: A long study of children treated with corticosteroids. J Pediatr 1966;68:507–515.
5.
Siegel NJ, Goldberg B, Krassner LS, Hayslett JP: Long-term follow-up of children with steroid responsive nephrotic syndrome. J Pediatr 1972;81:251–258.
6.
International Study of Kidney Diseases in Children: Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 1978;13:159–165.
7.
Takeda A, Matsutani H, Niimura F, Ohgushi H: Risk factors for relapse in childhood nephrotic syndrome. Pediatr Nephrol 1996;10:740–741.
8.
Utermann G: The mysteries of lipoprotein(a). Science 1989;246:904–910.
9.
MBewu AD, Durrington PN: Lipoprotein(a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990;85:1–14.
10.
Loscalzo J: Lipoprotein(a): A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672–679.
11.
Muls E, Rossenneu M, Daneels Rschurgers M, Boelaert J: Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 1985;54:225–227.
12.
Thabet MA, Salcedo JR, Chan JC: Hyperlipidemia in childhood nephrotic syndrome. Pediatr Nephrol 1993;7:559–666.
13.
Garnotel R, Roussel B, Pennaforte F, Randoux A, Gillery P: Changes in serum lipoprotein(a) levels in children with corticosensitive nephrotic syndrome. Pediatr Nephrol 1996;10:699–701.
14.
Nakahara C, Kobayashi K, Hamaguchi H, Kanemoto K, Kashiwagi T, Matsui A: Plasma lipoprotein(a) levels in children with minimal lesion nephritic syndrome. Pediatr Nephrol 1999;13;657–661.
15.
Soulat T, Loyau S, Baudouin V, Maisonneuve L,, Hurtaud-Riux MF, Schlegel N, Loirat C, Angle-Cano E: Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding. Arteriscler Tromb Vasc Biol 2000;20;575–584.
16.
Doucet C, Mooser V, Gonbert S, Raymond F, Chapman J, Thillet J: Plasma lipoprotein(a) in the nephrotic of lipoprotein(a) and apolipoprotein(a) in plasma and urine. JASN 2000:11;13;507–513.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.